Becton Dickinson vs Boston Scientific
Becton Dickinson reported revenue of $21.8 billion in fiscal 2025, about the same as Boston Scientific's $20.1 billion in fiscal 2025. Becton Dickinson's revenue grew 8.2% in its latest year, and Boston Scientific's grew 19.9%. Becton Dickinson had an operating margin of 11.8%, against 18.0% at Boston Scientific. Free cash flow was $2.7 billion at Becton Dickinson and $3.7 billion at Boston Scientific. Their fiscal years end in different months (September 30 and December 31), so the periods don't line up exactly.
Side by side
| Becton Dickinson | Boston Scientific | |
|---|---|---|
| Latest fiscal year | FY2025, Sep 30, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $21.8B | $20.1B |
| Revenue growth | 8.2% | 19.9% |
| Revenue growth a year, last 5 years | 6.3% | 15.2% |
| Gross margin | 45.4% | 69.0% |
| Operating margin | 11.8% | 18.0% |
| Net margin | 7.7% | 14.4% |
| Free cash flow | $2.7B | $3.7B |
| Free cash flow margin | 12.2% | 18.2% |
| Return on capital | 5.5% | 9.6% |
| Net debt to EBITDA | 3.4x | 1.8x |
| Dividends and buybacks | $2.2B | $0M |
| Change in diluted share count | −0.9% | 0.6% |
| Last close | $196.39 | $45.58 |
| P/E at the last close | 59.2× | 18.5× |
| Insider trades, last 12 months | sold $2.8 million | bought $10.0 million, sold $24.3 million |
| Piotroski F-score | 6 of 9 | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Becton DickinsonBoston Scientific
Operating margin
Percent of revenue
Becton DickinsonBoston Scientific
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Becton DickinsonBoston Scientific
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Becton Dickinson and Boston Scientific pages.